{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:00Z","timestamp":1792089420437,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HR2018-104"],"award-info":[{"award-number":["Y-HR2018-104"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.esmoop.2024.102239","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T18:14:53Z","timestamp":1707243293000},"page":"102239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-3139","authenticated-orcid":false,"given":"L.","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-7250","authenticated-orcid":false,"given":"J.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.102239_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A\u00a0global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2024.102239_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2024.102239_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.102239_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102239_bib5","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102239_bib6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41585-021-00483-z","article-title":"Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer","volume":"18","author":"Li","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.esmoop.2024.102239_bib7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/hep.32447","article-title":"Emerging immunotherapy for HCC: a guide for hepatologists","volume":"75","author":"Foerster","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2024.102239_bib8","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1002\/cam4.4845","article-title":"Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer","volume":"11","author":"Huang","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2024.102239_bib9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/pharmaceutics13070949","article-title":"Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.esmoop.2024.102239_bib10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2024.102239_bib11","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102239_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1006\/scbi.2000.0336","article-title":"Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015","volume":"10","author":"McCormick","year":"2000","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.esmoop.2024.102239_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O\u2019Shea","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2024.102239_bib14","article-title":"Oncolytic virus-based hepatocellular carcinoma treatment: current status, intravenous delivery strategies, and emerging combination therapeutic solutions","volume":"18","author":"Li","year":"2023","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.esmoop.2024.102239_bib15","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3748\/wjg.v17.i18.2353","article-title":"Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma","volume":"17","author":"He","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.esmoop.2024.102239_bib16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1186\/s12885-015-1715-x","article-title":"Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)","volume":"15","author":"Lin","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2024.102239_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9084852","article-title":"Prognostic comparison between cTACE and H101-TACE in unresectable hepatocellular carcinoma (HCC): a propensity-score matching analysis","volume":"2022","author":"Yao","year":"2022","journal-title":"Appl Bionics Biomech"},{"key":"10.1016\/j.esmoop.2024.102239_bib18","article-title":"A\u00a0recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study","volume":"11","author":"Zhang","year":"2021","journal-title":"Fron Oncol"},{"key":"10.1016\/j.esmoop.2024.102239_bib19","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","article-title":"Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial","volume":"10","author":"Lu","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.esmoop.2024.102239_bib20","first-page":"1666","article-title":"[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1016\/j.esmoop.2024.102239_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2024.102239_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100884","article-title":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","volume":"8","author":"Hecht","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.102239_bib23","article-title":"Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma","volume":"11","author":"Weng","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.102239_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.esmoop.2024.102239_bib25","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-21-3275","article-title":"Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab\u00a0+ bevacizumab treatment of hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102239_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110019","article-title":"Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors: a pooled analysis of 44 retrospective sudies","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.esmoop.2024.102239_bib27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.102239_bib28","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102239_bib29","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.102239_bib30","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u22651% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102239_bib31","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1158\/1078-0432.CCR-22-0657","article-title":"Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer","volume":"28","author":"Schoenfeld","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102239_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.4637","article-title":"Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer","volume":"5","author":"Zhuo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2024.102239_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","article-title":"Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment","volume":"18","author":"Cassidy","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.esmoop.2024.102239_bib34","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.102239_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","article-title":"Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results","volume":"73","author":"Motzer","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2024.102239_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106959","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: a meta-analysis of results from multivariate analysis","volume":"107","author":"Lin","year":"2022","journal-title":"Int J Surg"},{"key":"10.1016\/j.esmoop.2024.102239_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for\u00a0patients with malignant ascites: characterization of clinical efficacy\u00a0and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.esmoop.2024.102239_bib38","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1038\/s41467-023-40028-z","article-title":"A\u00a0phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors","volume":"14","author":"Zibelman","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.102239_bib39","article-title":"Adaptive virotherapy strategy for organism with constrained input using medicine dosage regulation mechanism","author":"Sun","year":"2023","journal-title":"IEEE Trans Cybern"},{"key":"10.1016\/j.esmoop.2024.102239_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","article-title":"First oncolytic viral therapy for melanoma","volume":"6","author":"Poh","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.102239_bib41","article-title":"Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1","volume":"11","author":"Hoang","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.102239_bib42","article-title":"Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases","volume":"11","author":"Yang","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.102239_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202370197","article-title":"Inhibition of tumor metastasis by liquid nitrogen-shocked tumor cells with oncolytic viruses infection","volume":"35","author":"Wu","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.esmoop.2024.102239_bib44","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.1021\/acsnano.6b06182","article-title":"Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.esmoop.2024.102239_bib45","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102239_bib46","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J\u00a0Hepatol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:31:21Z","timestamp":1761856281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2059702924000073"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102239","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102239"}}